The Protocol Review and Monitoring System (PRMS) continues to have as its major goal the assurance of the quality of the clinicaL research at the M.D. Anderson Cancer Center. PRMS consists of three major elements. Fist, the Clinical Research Committee and Psychosocial, Behavioral and Health Services Research Committee review the scientific aspects of protocols. This review includes the determination of validity of the scientific question, the appropriateness of the design of the study, the applicability of the proposed biostatistical methods of analysis, and the feasibility of the study reaching its state objectives. Second, the Protocol Data Management System (PDMS) must be used to register all patients of clinical trials. An eligibility checklist must be successfully completed prior to patient registration and release of drug from the pharmacy. Thus, a single database now exists in which clinical trials patient information is deposited for review and audit. Third, the Office of Clinical Research Quality Assurance audits the performance of the trial with the approved protocol and the agreement of the PDMS database with the patient record (two random audits per month). Thus, critical elements of the Clinical Trials Support Resource Core constitute the various checkpoints for PRMS process. Protocol prioritization remains the responsibility of the clinical departments. This is because the major expertise for prioritization of disease-specific protocols resides in these departments. However, the committees reviewing the scientific of proposals can disapprove or make approval contingent upon appropriate prioritization of protocols at any time during the review process. Further, the Office of Clinical Research Quality Assurance has received investigators' requests to close over 100 protocols following a detailed review of accrual done by that office. This is a regular, on-going activity of this office (every 6 months). Using this three-part system, we have developed a PRMS that assures the highest standards of peer-reviewed clinical research, a system of random audits, and an institution-wide database that allows auditing and data monitoring functions to occur rapidly and with minimal disruption to on- going work.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-25S1
Application #
6347277
Study Section
Project Start
2000-08-30
Project End
2001-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications